Celldex Therapeutics (CLDX) Share-based Compensation (2010 - 2026)

Celldex Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 8.51% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $35.4 million (down 2.56% YoY), while the FY2025 annual figure was $36.2 million, up 5.77% from the prior year.
• Share-based Compensation was $8.5 million for Q1 2026 at Celldex Therapeutics, down from $8.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.8 million in Q4 2024 to a low of $3.2 million in Q1 2022.
• Historically, Share-based Compensation has averaged $7.0 million across 5 years, with a median of $7.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 147.29% in 2022, then retreated 8.91% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $4.5 million in 2022, then soared by 59.98% to $7.2 million in 2023, then soared by 35.61% to $9.8 million in 2024, then decreased by 8.91% to $8.9 million in 2025, then slipped by 4.33% to $8.5 million in 2026.
• The last three Share-based Compensation figures came in at $8.5 million (Q1 2026), $8.9 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.